Jennifer Schmitke
Chief Operating Officer at IMV INC.
Jennifer Schmitke active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IMV INC. | Chief Operating Officer | - | - |
Career history of Jennifer Schmitke
Former positions of Jennifer Schmitke
| Companies | Position | Start | End |
|---|---|---|---|
| EPIZYME, INC. | Corporate Officer/Principal | - | 01/04/2022 |
| BIOGEN INC. | Director/Board Member | - | - |
| OMEGA THERAPEUTICS, INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Training of Jennifer Schmitke
| Queen's University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistics
International
| United States | 6 |
| Canada | 3 |
Operational
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 2 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| OMEGA THERAPEUTICS, INC. | Health Technology |
| IMV INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Private companies | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Jennifer Schmitke
- Experience
